Christy Jones - 31 Jan 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Director
Signature
/s/ Stephen Feider, Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Feb 2025, 20:30:12 UTC
Previous filing
29 Jan 2025
Next filing
18 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBNX Director Stock Option (right to buy) Award $0 +9,137 $0.000000 9,137 31 Jan 2025 Common Stock 9,137 $7.51 Direct F1, F2
transaction BBNX Director Stock Option (right to buy) Award $0 +9,137 $0.000000 9,137 31 Jan 2025 Common Stock 9,137 $7.51 Direct F2, F3
transaction BBNX Director Stock Option (right to buy) Award $0 +48,730 $0.000000 48,730 31 Jan 2025 Common Stock 48,730 $7.51 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in 36 equal monthly installments measured from April 27, 2021.
F2 Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
F3 The shares subject to this option shall vest in 36 equal monthly installments measured from July 20, 2021.
F4 The shares subject to this option shall vest in 48 equal monthly installments measured from July 27, 2022.